- About Us
- Investment News
Biogen Korea, the Korean unit of American multinational biotech company Biogen Inc. Monday named Hwang Se-eun as its fresh chief executive, completing an organizational structure for local business after its founding last July.
Biogen which reported $11.44 billion in worldwide revenue last year has earned fame as an original developer of targeted cancer drug Mabthera marketed by Swiss pharmaceutical giant Roche. Mabthera is an originator drug of Truxima, a biosimilar from Korea’s Celltrion.
Biogen became familiar to the public in 2012 when it created Samsung Bioepis as a joint venture with Samsung BioLogics. Biogen holds a 5.4 percent stake in Samsung Bioepis. Biogen is responsible for marketing biosimilar products of Samsung Bioepis in Europe.
Hwang worked in various roles at Korean and multinational pharmaceutical companies including JW Pharm, Merck Korea and Abbott Korea. Prior to the new role, she led a business strategy team at Handok Pharm to market orphan drugs in Korea for U.S.-based Alexion Pharmaceuticals.
Biogen is waiting for marketing approval from Korean health authorities for its spinal muscular atrophy drug Spinraza (nusinersen).
By Shin Chan-ok and Minu Kim
Copyrights Pulse by Maeil Business News Korea. All Rights Reserved.
Source: Pulse by Maeil Business News Korea (Nov. 27, 2017)